Definition and concept of metabolic syndrome. Differences and similarities in the diagnosis and clinical practice;Definición y concepto del síndrome metabólico. Diferencias y similitudes en el diagnóstics y la práctica clínica

Medicina Clinica Monografias

Volumn 7, Issue 4, 2006, Pages 2-7

  Orozco Beltrán, Domingo ^a   Suárez Fernández, Carmen ^b   Serrano Ríos, Manuel ^c  

^a Centro de Salud Babel   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CLINICAL PRACTICE; CONSENSUS; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; SYNDROME DELINEATION;

EID: 33750452253     PISSN: 15771512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595-600.
2. American Diabetes Association of Clinical Endocrinologists. Code for dysmetabolic syndrome X. Disponible en: www.aace.com.
3. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome -a new worldwide definition. Lancet. 2005;366:1059-62.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
5. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575-81.
6. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004; 110:1251-7.
7. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, et al. WHO and ATP III proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004;21:383-7.
8. Grundy SM, Cleeman JI, Daniels SR, Donate KA, Eckel RH, Franklin BA, et al, American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
9. Enkhmaa B, Shiwaku K, Anuurad E, Nogi A, Kitajima K, Yamasaki M, et al. Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evauation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians. Clin Chim Acta. 2005;352:105-13.
10. Shah T, Jonnalagadda SS, Kicklighter JR, Diwan S, Hopkins BL. Prevalence of metabolic syndrome risk factors among young adult Asian Indians. J Immigr Health. 2005;7:117-26.
11. Shiwaku K, Nogi A, Kitajima K, Anuurad E, Enkhmaa B, Yamasaki M, et al. Prevalence of the metabolic syndrome using the modified ATP III definitions for workers in Japan, Korea and Mongolia. J Occup Health. 2005;47:126.
12. Tankó LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111:1883-90.
13. WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Ginebra: Organización Mundial de la Salud; 1999.
14. The European Group for the study of Insulin Resistance (EGIR). The frequency of the WHO metabolic syndrome in european cohorts, an alternative definition of an insulin resistance syndrome. Diabet Med. 2002; 28:364-76.
15. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care. 2003;26:1297-303.
16. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-304.
17. Ford ES. Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the US. Diabetes Care. 2005; 28:2745-9.
18. Serrano Ríos M. The metabolic syndrome in Spain. El síndrome metabólico en su 80 aniversario. Actas del Segundo Simposio Científico. Madrid; 2002.
19. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
20. Lakka HM, Laaksonene DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomileto V. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged mean. JAMA. 2002;288:1709-16.
21. Crepaldi G. Origin and developmente of the metabolic syndrome. En: Serrano Ríos M, Caro JF, Carrara R, Gutiérrez-Fuentes JA, editores. The metabolic syndrome at the beginning of the 21th century. Madrid: Elsevier; 2005. p. 6-12.
22. Fernández-Real JM, Ricart W. Chronic inflammatory hypothesis en the metabolic syndrome. En: Serrano Ríos M, Caro JF, Carraro R, Gutiérrez-Fuentes JA, editores. The metabolic syndrome at the beginning of the 21th century. Madrid: Elsevier; 2005. p. 218-27.
23. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al, 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004; 93:136-41.
24. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769-78.
25. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metabol Clin N Am. 2004;33:283-303.
26. Reaven G. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286-8.
27. Consenso del Grupo de Trabajo de Resistencia a la Insulina de la Sociedad Española de Diabetes. Coordinador: Serrano-Ríos M. La Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes mellitus tipo 2. Med Clin (Barc). 2002;119:458-63.